These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 25801845)

  • 1. Social support decreases depressogenic effect of low-dose interferon alpha treatment in melanoma patients.
    Kovács P; Pánczél G; Balatoni T; Liszkay G; Gonda X; Bagdy G; Juhasz G
    J Psychosom Res; 2015 Jun; 78(6):579-84. PubMed ID: 25801845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depression in hospitalized patients with malignant melanoma treated with interferon-alpha-2b: primary to induced disorders.
    Navinés R; Gómez-Gil E; Puig S; Baeza I; De Pablo J; Martín-Santos R
    Eur J Dermatol; 2009; 19(6):611-5. PubMed ID: 19709980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy.
    Capuron L; Ravaud A; Miller AH; Dantzer R
    Brain Behav Immun; 2004 May; 18(3):205-13. PubMed ID: 15050647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trial.
    Heinze S; Egberts F; Rötzer S; Volkenandt M; Tilgen W; Linse R; Boettjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Hinzpeter A; Hauschild A; Schaefer M
    J Immunother; 2010 Jan; 33(1):106-14. PubMed ID: 19952950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
    Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
    J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma.
    Friebe A; Schwarz MJ; Schmid-Wendtner M; Volkenandt M; Schmidt F; Horn M; Janssen G; Schaefer M
    J Immunother; 2007 Apr; 30(3):333-7. PubMed ID: 17414324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychological changes in melanoma patients during ipilimumab treatment compared to low-dose interferon alpha therapy-a follow-up study of first experiences.
    Kovács P; Pánczél G; Borbola K; Juhász G; Liszkay G
    Pathol Oncol Res; 2014 Oct; 20(4):939-44. PubMed ID: 24771289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma.
    Friebe A; Horn M; Schmidt F; Janssen G; Schmid-Wendtner MH; Volkenandt M; Hauschild A; Goldsmith CH; Schaefer M
    Psychosomatics; 2010; 51(6):466-73. PubMed ID: 21051677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha.
    Satzger I; Meier A; Schenck F; Kapp A; Hauschild A; Gutzmer R
    Int J Cancer; 2007 Dec; 121(11):2562-6. PubMed ID: 17680564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated.
    Bannink M; Kruit WH; Van Gool AR; Sleijfer S; van der Holt B; Eggermont AM; Stoter G; Hengeveld MW
    Psychosomatics; 2008; 49(1):56-63. PubMed ID: 18212177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial.
    Hauschild A; Weichenthal M; Rass K; Linse R; Berking C; Böttjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Stein A; Näher H; Schadendorf D; Mohr P; Kaatz M; Tronnier M; Hein R; Schuler G; Egberts F; Garbe C
    J Clin Oncol; 2010 Feb; 28(5):841-6. PubMed ID: 20048184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma.
    Hauschild A; Weichenthal M; Rass K; Linse R; Ulrich J; Stadler R; Volkenandt M; Grabbe S; Proske U; Schadendorf D; Brockmeyer N; Vogt T; Rompel R; Kaufmann R; Kaatz M; Näher H; Mohr P; Eigentler T; Livingstone E; Garbe C
    J Clin Oncol; 2009 Jul; 27(21):3496-502. PubMed ID: 19433681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed wound healing following treatment with low-dose interferon alfa-2b for cutaneous melanoma.
    Ammoury AF; El Sayed F; Bazex J
    Arch Dermatol; 2007 Oct; 143(10):1339-40. PubMed ID: 17938359
    [No Abstract]   [Full Text] [Related]  

  • 14. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?
    Schuchter LM
    J Clin Oncol; 2004 Jan; 22(1):7-10. PubMed ID: 14665612
    [No Abstract]   [Full Text] [Related]  

  • 15. [Alpha-interferon and mental disorders].
    Debien C; De Chouly De Lenclave MB; Foutrein P; Bailly D
    Encephale; 2001; 27(4):308-17. PubMed ID: 11686052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha.
    Schaefer M; Horn M; Schmidt F; Schmid-Wendtner MH; Volkenandt M; Ackenheil M; Mueller N; Schwarz MJ
    Brain Behav Immun; 2004 Nov; 18(6):555-62. PubMed ID: 15331126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year--a Hellenic Cooperative Oncology Group study.
    Gogas H; Bafaloukos D; Ioannovich J; Skarlos D; Polyzos A; Fountzilas G; Kalofonos HP; Aravantinos G; Tsoutsos D; Panagiotou P; Frangia K; Petrakopoulou T; Pectasides D;
    Anticancer Res; 2004; 24(3b):1947-52. PubMed ID: 15274382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early signs of liver failure after low-dose interferon alfa-2b for cutaneous melanoma.
    Ammoury A; El Sayed F; Farah C; Bazex J
    J Am Acad Dermatol; 2008 Mar; 58(3):532-3. PubMed ID: 18280369
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of adjuvant interferon-alpha low-dose therapy in melanoma patients on serum inhibin B.
    Karamfilov T; Wollina U; Hipler UC; Graefe T; Schreiber G
    J Dermatol; 2000 Oct; 27(10):639-42. PubMed ID: 11092267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma.
    Daud A; Soon C; Dummer R; Eggermont AM; Hwu WJ; Grob JJ; Garbe C; Hauschild A
    Expert Opin Biol Ther; 2012 Aug; 12(8):1087-99. PubMed ID: 22694288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.